Galmed Pharmaceuticals Ltd Expected to Earn FY2022 Earnings of $0.03 Per Share (GLMD)

Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) – Equities researchers at SunTrust Banks issued their FY2022 earnings estimates for shares of Galmed Pharmaceuticals in a note issued to investors on Thursday. SunTrust Banks analyst E. Nash anticipates that the biopharmaceutical company will post earnings of $0.03 per share for the year.

Several other research firms have also issued reports on GLMD. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Galmed Pharmaceuticals in a research report on Friday, October 27th. Maxim Group set a $14.00 price target on shares of Galmed Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. Zacks Investment Research upgraded shares of Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.50 price target on the stock in a research report on Tuesday, November 14th. ValuEngine lowered shares of Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 14th. Finally, Roth Capital began coverage on shares of Galmed Pharmaceuticals in a research report on Wednesday, November 15th. They issued a “buy” rating and a $32.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $20.40.

Galmed Pharmaceuticals (NASDAQ:GLMD) traded down $1.04 during midday trading on Monday, hitting $5.92. 239,200 shares of the company were exchanged, compared to its average volume of 112,136. Galmed Pharmaceuticals has a fifty-two week low of $3.61 and a fifty-two week high of $12.22. The firm has a market capitalization of $75.38, a price-to-earnings ratio of -5.33 and a beta of 2.42.

A number of institutional investors have recently bought and sold shares of GLMD. Deutsche Bank AG purchased a new position in Galmed Pharmaceuticals during the 4th quarter worth approximately $246,000. Renaissance Technologies LLC purchased a new position in Galmed Pharmaceuticals during the 4th quarter worth approximately $345,000. J. Goldman & Co LP purchased a new position in Galmed Pharmaceuticals during the 4th quarter worth approximately $569,000. Sphera Funds Management LTD. purchased a new position in Galmed Pharmaceuticals during the 4th quarter worth approximately $2,164,000. Finally, Park West Asset Management LLC grew its position in Galmed Pharmaceuticals by 4.4% during the 4th quarter. Park West Asset Management LLC now owns 292,847 shares of the biopharmaceutical company’s stock worth $2,679,000 after purchasing an additional 12,347 shares in the last quarter. Hedge funds and other institutional investors own 11.90% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Galmed Pharmaceuticals Ltd Expected to Earn FY2022 Earnings of $0.03 Per Share (GLMD)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.dispatchtribunal.com/2018/02/20/galmed-pharmaceuticals-ltd-expected-to-earn-fy2022-earnings-of-0-03-per-share-glmd.html.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

Earnings History and Estimates for Galmed Pharmaceuticals (NASDAQ:GLMD)

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply